(Q34608618)

3 August 2017

1 reference

title

Endocrine and clinical endpoints of exemestane as neoadjuvant therapy (English)

1 reference

3 August 2017

William R Miller

1

1 reference

3 August 2017

J Michael Dixon

series ordinal

2

1 reference

3 August 2017

publication date

1 March 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

9

1 reference

3 August 2017

issue

2 Suppl

1 reference

3 August 2017

page(s)

9-15

1 reference

The interconversion and aromatization of androgens by human adipose tissue

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327480200902S02

Aromatization of androstenedione by cultured human fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200902S02

Oestradiol synthesis from C19 steroids by human breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200902S02

Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200902S02

Aromatase within the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200902S02

Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200902S02

Lessons from the use of aromatase inhibitors in the neoadjuvant setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200902S02

10.1177/107327480200902S02

21 January 2018

Identifiers

DOI

0 references

1 reference